Nano4 Global has been selected for the SME Instrument Phase 2 initiative of Horizon 2020, a very competitive initiative. It was one of the few companies from life science field to be selected.
MagicCELLGene aims at developing a disruptive new technology DNA/RNAi transfection - magiccellgene.wixsite.com/magiccellgene. MagicCELLGene focus on the site directed magnetic hyperthermia that creates focal hotspots on the cell membrane to allow the entry of therapeutic nucleic acids, with potential clinical applications in cell-based gene therapy.
The Gilead Genese Prize will be instrumental for the construction of the capture MNPs and validation of molecular assays on patient samples. This endeavor is only possible due to the long-lasting collaboration between IHMT-NOVA TB Group lead by Miguel Viveiros and João Piedade for HIV and the Nanomedicine Group lead by Pedro V. Baptista at UCIBIO, Dept of Life Sciences, FCT-NOVA.
Scientists at UCIBIO, FCT, Universidade NOVA de Lisboa have demonstrated for the first time the potential use of smart nanomaterials for the effective modulation of angiogenesis in vivo.
